

AD _____

Award Number: DAMD17-99-1-9327

TITLE: Insulin and Breast Cancer Risk

PRINCIPAL INVESTIGATOR: Paola Muti, M.D.

CONTRACTING ORGANIZATION: State University of New York
Amherst, New York 14228

REPORT DATE: June 2001

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20010925 226

reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2001	3. REPORT TYPE AND DATES COVERED Annual (1 Jun 00 - 31 May 01)	
4. TITLE AND SUBTITLE Insulin and Breast Cancer Risk			5. FUNDING NUMBERS DAMD17-99-1-9327	
6. AUTHOR(S) Paola Muti, M.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) State University of New York Amherst, New York 14228 E-MAIL: muti@acsu.buffalo.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) There is evidence suggesting that life-style factors play a significant role in breast cancer (BC) development. Insulin, which secretion is influenced by life-style factors, might represent the possible etiological linkage between lifestyle characteristics and BC. Insulin might act in the carcinogenetic process through mitogenic effect on breast epithelium. Furthermore, insulin modulates an additional proliferative and hormone-regulating factor which may be involved in the etiology of BC: the Insulin-like Growth Factor I (IGF-I). The investigators have proposed to test the hypothesis of the linkage between serum insulin and BC in an Italian prospective cohort study conducted to investigate the role of hormones and diet in the etiology of BC (the ORDET study). 10,788 healthy volunteer women, aged 35-69, residents in Varese province, an area covered by the Lombardy Cancer Registry, were enrolled between June 1987 and June 1992. At the recruitment, blood samples were collected between 8:00 and 9:30 A.M., after an overnight fast, and stored at -80° C. During the first seven years of follow-up, the cancer registry identified 144 breast cancer cases. The study compares pre-diagnostic serum levels of insulin, IGF-I, free IGF-I, and IGF-I binding proteins (IGFBP-1 and IGFBP-3) for the BC cases and 576 controls (four per BC case) randomly selected from the cohort women who did not develop BC during same follow-up period, matched on age, menopausal status, recruitment center, and recruitment period.				
14. SUBJECT TERMS Breast Cancer			15. NUMBER OF PAGES 13	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

W Where copyrighted material is quoted, permission has been obtained to use such material.

W Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

W Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

W In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

N/A In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

Bob Li

6/25/01

PI - Signature

Date

Table of Contents

Cover.....	1
SF 298.....	2
Foreword.....	3
Introduction.....	5
Body.....	6
Key Research Accomplishments.....	11
Reportable Outcomes.....	11
Conclusions.....	11
References.....	12
Appendices.....	13

Introduction

The primary purpose of this study is to examine insulin and insulin-growth-factor pattern in relation to breast cancer etiology. In addition, it also evaluates the possible concomitant role of sex steroids in the causal relation with breast cancer.

In this prospective cohort study, 10,788 healthy volunteer women, aged 35-69, residents in Varese province, an area covered by the Lombardy Cancer Registry, were enrolled between June 1987 and June 1992. At the recruitment, blood samples were collected between 8:00 and 9:30 A.M., after an overnight fast, and stored at -80° C. During the first seven years of follow-up, the cancer registry identified 144 breast cancer cases. The proposed study will compare pre-diagnostic serum levels of insulin, IGF-I, free IGF-I, and IGF-I binding proteins (IGFBP-I and IGFBP-3) for the BC cases and 576 controls (four per BC case) randomly selected from the cohort women who did not develop BC during same follow-up period, matched on age, menopausal status, recruitment center, freezer and position within the freezer, recruitment period, and recruitment within the same daylight saving period. The proposed study represents the first attempt to evaluate the association of insulin and IGF-I with BC using data from a cohort prospective study in which several potential sources of hormone variability have been controlled for by study design.

Insulin may play an important role in the etiology of breast cancer. Insulin, in fact, is a powerful mitogenic agent inducing a dose-dependent growth response in BC cell lines acting via its own receptor. In addition, insulin may play a role in tumor promotion by upregulation of ovarian steroid secretion. In fact, chronic hyperinsulinemia has been implicated in the etiopathogenesis of hyperandrogenic status and hypothesized as a determinant of this hormonal pattern. Furthermore, insulin may act as a tumor promoter through its effect on insulin-like growth factor-I (IGF-I): IGF-I is a structural homologue of insulin, characterized by both mitogenic, and gonadotropic action of its own.

In spite of the very strong physiological evidence for a role of insulin in BC etiology, very limited evidence has been presented in epidemiological studies. To date, only two case-control studies have been conducted on serum insulin and BC risk and the results of both studies supported the association. IGF-I has also been associated with breast cancer in several case-control studies. However, these case-control studies were relatively small, blood was collected in a non-fasting state, and there was no control of other potential sources of hormone variability (i.e., circadian rhythm). The only cohort study on this question showed a seven fold elevation in BC risk between the highest and the lowest tertile of IGF-I among premenopausal women. However, this study evaluated only total IGF-I serum levels, lacking description of other potential hormone/metabolic determinants of the disease.

Body Of Report

During the second budget year, we assayed the 720 samples (144 samples from breast cancer cases and 576 from control women), for Insulin, and glucose. For Insulin-Like-Growth-Factor 1, Free Insulin-Like-Growth-Factor, Insulin-Like-Growth-Factor Binding Globulin 1, Insulin-Like-Growth-Factor Binding Globulin 2, Insulin-Like-Growth-Factor Binding Globulin 3 we have completed an investigative phase to assess the most accurate assay method to use for population based studies. Several immunoassays have been developed to measure total IGF-I in serum or plasma. Hitherto, no autoantibodies have been raised which detect IGF-I bound to IGFBPs in the binary or ternary complexes. Therefore, in our study we identified the need to dissociate and separate IGF-I from IGFBPs before determination by radioimmunoassay using acid ethanol extraction, which is the most common technique, applied. Thus, we have now started and completed the extraction of IGF-I and its binding proteins 1, 2, 3 for more than half of the study subjects.

As a consequence, in the present annual report, we include the preliminary but complete findings of insulin and glucose in relation to breast cancer risk. The findings are here reported in the appendix section as an abstract accepted as oral communication at the Annual Meeting of the American Association Cancer Research in New Orleans, April 2001 and at the Annual Meeting of the Society for Epidemiological Research (Toronto, June 2001).

Publications

At the present time, there are no results or publications coming directly from this grant because we have completed only part of the analytical determinations. However, Dr. Muti has completed an additional study on breast cancer conducted within the ORDET cohort. The study concerns blood red cell fatty acid composition and risk of breast cancer. Since, variations in fat consumption and metabolism are suspected to contribute to the marked regional differences in breast cancer incidence rates, the fatty acid composition of the erythrocyte membrane may be an appropriate biomarker for investigating the relation of dietary fat and patterns of fatty acid metabolism to breast cancer. The association between prediagnostic red cell membrane fatty acid and postmenopausal breast cancer risk was analyzed among postmenopausal breast cancer cases and controls members of the ORDET study. Red cell membranes were separated and membrane phospholipids fatty acids were measured as a percentage of total fatty acid. Conditional logistic regression analysis was performed to test the association between the membrane's fatty acid composition and breast-cancer risk. The Saturation Index (SI), a ratio between membrane stearic and oleic that depends on the activity of the enzyme delta9-CoA (Δ^9 -d) desaturase has been also tested. The study results showed positive associations with breast-cancer risk were detected for oleic (OR=2.72; CI=1.26-5.91) and monounsaturated fatty acids (OR=3.9; CI=1.66-9.18). SI was

inversely associated to breast-cancer risk (OR=0.40; CI= 0.19-0.85) as well as linoleic acid (OR=0.42; CI=0.19-0.94). No significant association was detected with saturated fatty acids or with n-3 PUFA. Although the relative importance of diet in regulating the fatty acid composition of membranes remains to be fully determined, study results strongly indicate that oleic and monounsaturated fat components of the red blood cells are relevant predictors of breast cancer. The observed inverse association between breast cancer and membrane saturation index suggests the need of further studies connecting the pattern of its multiple determinants (dietary, metabolic, hormonal) to the development of breast cancer. Results from that study are in publication in the Journal of National Cancer Institute (see references Pala V.et al., JNCI).

Dr. Muti also completed a study on measurement variability of plasma β -sitosterol and campesterol during the past academic year. Phytosterols are plant sterols, which are structurally similar to cholesterol and characterized by anti-carcinogenic and anti-atherogenic properties. β -Sitosterol and campesterol are the predominant phytosterols in blood. The study was aimed to analyze reproducibility and overtime reliability of plasma β -sitosterol and campesterol measurements. In order to study reproducibility of the measurement (technical variability), three healthy premenopausal women donated a sample of their blood. Each blood sample was subdivided into six aliquots and analyzed within the same run by the same laboratory technician. The intraclass correlation coefficients (ICCs) of the assay for plasma β -sitosterol and campesterol were

0.88 and 0.94 (95% Confidence Interval low bounds [95% CI_{low}] were 0.66 and 0.82), respectively. To study reliability of β -sitosterol and campesterol measurement over time, seven premenopausal women were recruited. Over a six-month period, each woman provided once a month a fasting blood sample at the same time of day, and the same numerical day of luteal phase of menstrual cycle (between the 20th and the 24th day of the menstrual cycle). All plasma samples from the same individual were processed together at the same time by the same technician at the end of the six-month period. The overtime ICCs of plasma β -sitosterol and campesterol were 0.91 (95% CI_{low} 0.49) and 0.58 (95% CI_{low} 0.31), respectively. The high reproducibility and the good overtime reliability of plasma β -sitosterol and campesterol measurements indicate that they may be suitable for potential clinical and population based studies on cancer prevention. Mrs. Jianhong Li, a student working with Dr. Muti, used that study as her master thesis (see reference Li JH, et a., 2001)

In the past year Dr. Muti has collaborate in a study on methylation and breast cancer risk with Dr. Jo Freudenheim which resulted in an additional presentation to the Annual Meeting of the American Association Cancer Research in New Orleans (2001) and in a manuscript in preparation (see references for the abstract presentation).

In addition, she participated in the analysis of the effects of Luteinizing Hormone and Follicular Stimulating Hormone on the risk of breast

cancer. The study was conducted on the same groups of premenopausal women (breast cancer cases and controls) members of the ORDET cohort study. Results showed that the two protein hormones have protective effect on breast cancer. The data have been presented at the international meeting of the population based cancer registries of Latin countries (ORDET cohort is followed up by the Lombardy Cancer Registry) in Neuchâtel, Switzerland, Spring 2001, and at the annual meeting of the Italian Cancer Registries, Alghero, Italy, Spring 2001 (see references for the abstract presentations).

Dr. Muti has also conducted a study based on a DOD funded case-control study and in collaboration with the Department of Microbiology at the Johns Hopkins University, MD on the influence of human papillomavirus (HPV) on prostate cancer risk. Data showed that the prevalence of HPV infection was higher in prostate cancer cases than in controls. Data were presented by Dr. Womak, a NCI postdoctoral fellow working with Dr. Muti, at the Professional Development Workshop, sponsored by the Comprehensive Minority Biomedical Branch (CMBB), Office of Deputy Director for Extramural Science (ODDES), at the National Cancer Institute, June 2001 (see references for the abstract presentation).

Dr, Muti has also in publication studies regarding indices of oxidative stress and risk of chronic diseases. The studies were conducted using a dataset

developed at the Department of Social and Preventive Medicine with the collaboration of five different population-based studies (see references).

Key Research Accomplishments

- Biochemical analyses completed (Insulin, glucose)
- Statistical analysis performed for insulin and glucose
- Biochemical analyses for IGF-I, IGFBP-1, 2, 3 completed for more than half of the study members

Reportable Outcomes

Glucose metabolism showed to be involved in breast cancer development in premenopausal but not in postmenopausal women.

Conclusions

Analytical determinations of IGF-I, IGFBP-1, 2, 3 are underway. This information will further clarify the role of glucose and its metabolism in breast cancer etiology.

References

- Pala V, Krogh V, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F, **Muti P**. *Prospective investigation of red blood cell fatty acid and post-menopausal breast cancer*(in press, Journal of National Cancer Institute)
- Li JH, Awad AB, Fink CS, Wu YW, Hill L, Trevisan M, **Muti P**. *Measurement variability of plasma β -sitosterol and campesterol, two new biomarkers for cancer prevention* (in press, European Journal of Cancer Prevention)
- Freudenheim JL, Bonner M, Krishnan S, Ambrosone C, Graham S, **Muti P**, Vena J, Moysich K, Shields P. *Epidemiology of One-Carbon Metabolism and p53 Mutational Spectra in Breast Cancer* American Association Cancer Research, New Orleans, LA, USA, March 2001
- Micheli A, **Muti P**, Krogh V, Mugno E, Sieri S, Pala V, Meneghini E, Cifala' A, Berrino F. *ORDET: fattori di rischio in donne in postmenopausal in uno studio prospettico*. XXVI Reunion Du Groupe Pour L'epidemiologie Et L'enregistrement Du Cancer Dans Les Pays De Langue Latine, Neuchâtel (Switzerland), May 24-25, 2001
- Micheli A, **Muti P**, Krogh V, Secreto G, Mugno E, Sieri S, Pala V, Crosignani P, Berrino F. *ORDET: livelli di gonadotropine sono associati al rischio di tumore della mammella in donne in età fertile*. V Riunione Scientifica Annuale dell'Associazione Italiana Registri Tumori.,Alghero, Italy, March 29-30, 2001
- Womack S, **Muti P**, Viscidi R, Shah KV. *Human papillomavirus seropositivity in PROMEN case and control study participants*. Professional Development Workshop, sponsored by the Comprehensive Minority Biomedical Branch (CMBB), Office of Deputy Director for Extramural Science (ODDES), and National Cancer Institute; June 4-6, 2001.
- Schisterman E, Faraggi D, Brown R, Freudenheim JL, Dorn J, **Muti P**, Armstrong D, Trevisan M. *TBARS and cardiovascular disease in a population-based sample* (in press, Journal of Cardiovascular Risk)
- Schünemann HJ, Garnt BJ, Freudenheim JL, **Muti P**, Browne RW, Drake JA, Klocke RA, Trevisan M. *The relation of serum levels of antioxidant vitamins C and E, retinol, and carotenoids with pulmonary function in the general population* Am J Respir Crit Care Med 2001; 163: 1246-1255

Appendices

Muti P, Quattrin T, Misciagna G, Krog V, Micheli A, Browne R, Berrino F. Fasting serum glucose and insulin and breast cancer risk in premenopausal and postmenopausal women: the ORDET study. *American Association Cancer Research, New Orleans, LA, USA, March 2001 [SER, Toronto, 2001].*

Fasting Glucose and Insulin: A Prospective Study

There is some evidence that glucose and other factors related to glucose metabolism, such as insulin may contribute to breast cancer development.

Objective To analyze the hypothesis that serum glucose, insulin levels are associated with breast cancer.

Design, setting and participants A nested case-control study design within a prospective cohort was conducted. From 1987 and 1992, 10,786 women aged 35-69 were recruited in a prospective study in Italy. At recruitment, blood samples were collected after 12 hours fast between 7:30 and 9:00 AM from all study participants. After 5.5 years, 144 breast cancer cases were identified among the participants of the cohort. Four matched controls were chosen for each breast cancer case from members of the cohort who did not develop breast cancer during the follow-up period.

Results In premenopausal women, glucose was associated with breast cancer risk: the age, BMI, and reproductive variable adjusted relative risk (RR) for the highest quartile of serum glucose versus the lowest was 2.8 [95% Confidence Interval (CI) 1.2 – 6.5], p for trend 0.02. Insulin showed a weaker association with breast cancer, the adjusted RR of the highest quartile versus the lowest was 1.7 (95% CI 0.7 – 4.1), p for trend 0.14. In postmenopausal women, none of the variables was associated with breast cancer risk.

Conclusions These results indicate that chronic alteration of glucose metabolism are related to breast cancer development in premenopausal women.